

**Data Sheet**

**NAME:** I50V (HIV-1 Drug (Protease Inhibitor) Resistant Variant)

**REPOSITORY REFERENCE:** ARP1008

**DERIVATION:** Derived from HXB2 by in vitro selection with protease inhibitor (VX-478). Protease mutation I→V at position 50.

**ORIGINATORS DESIGNATION:** Protease Mutant I50V

**CHARACTERISTICS:** Confers slight resistance (two – threefold) to protease inhibitors VX-478 & VB-11, 328.

**CELLS FOR PROPAGATING:** MT4

**PRESENTATION:** Supplied as cell-free culture supernatants from MT4 cells.

**CULTURE MEDIUM:** RPMI 1640, Foetal calf serum 10%

**SOURCE:** Drs M Tisdale & E D Blair, Glaxo Wellcome R & D, Herts.

**REFERENCE:** Tisdale M et al, (1995) Antimicrobial Agents and Chemotherapy 39: 1704 –1710.  
Partaledis JA et al, (1995) J Virol 69: 5228 – 5235.

**ACKNOWLEDGEMENTS:** Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html> in the “Acknowledgements” section.  
Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)